CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
Efficacy and safety of once weekly dulaglutide and once daily insulin glargine treatment at 52 weeks in patients with type 2 diabetes (T2DM) in the Assessment of Weekly AdministRation of dulaglutide in Diabetes-2 (AWARD-2) study, stratifie…
DOI 10.1055/s-0035-1549549
Bibliografische Angaben
Nachweis in CareLit
Autor:innenJ Vora, V Pechtner, N Jia, R Shaginian, O Adetunji
ZeitschriftDiabetologie und Stoffwechsel
Ausgabe04/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: We determined the impact of duration of diabetes (DoD) on the efficacy and safety of dulaglutide and insulin glargine treatment in patients with T2DM. Methods: Post hoc subgroup efficacy and safety analyses at 52 weeks were performed by baseline DoD (< 5, ≥5-< 10, ≥10 years) for patients (N = 807; mean [standard deviation] disease duration, 9.1 (6.0) years) receiving dulaglutide 1.5 mg (N = 273), dulag…
Zitieren
Zitierempfehlung
J Vora, V Pechtner, N Jia, R Shaginian, O Adetunji (2015) Efficacy and safety of once weekly dulaglutide and once daily insulin glargine treatment at 52 weeks in patients with type 2 diabetes (T2DM) in the Assessment of Weekly AdministRation of dulaglutide in Diabetes-2 (AWARD-2) study, stratified by duration of diabetes (< 5 years, ≥5 to < 10 years, ≥10…. Diabetologie und Stoffwechsel (04). https://doi.org/10.1055/s-0035-1549549
Mit CareLit weiterarbeiten